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Abstract
Type 1 diabetes (T1D) is an autoimmune disease with a prolonged and variable latent period that 
culminates in the destruction of pancreatic β-cells and the development of hyperglycemia. There is 
a need for diagnostic biomarkers to detect more accurately detect individuals with prediabetes to 
expedite targeting for prevention and intervention strategies. To assess the current ability to 
predict the insidious development of T1D, we conducted a comprehensive systematic review for 
established and prospective predictive markers of T1D using the Medline, OVID, and EMBASE 
databases. Resulting citations were screened for relevance to subject. Our research generated five 
major categories of markers that are either currently used or forthcoming: genetic, autoantibodies, 
risk score quantification, cellular immunity, and β-cell function. The current standard used to 
assess T1D onset or predisposition focuses on autoimmune pathology and disease-associated 
autoantibodies. Research studies in general go beyond autoantibody screening and assess genetic 
predisposition, and quantitate risk of developing disease based on additional factors. However, 
there are few currently used techniques that assess the root of T1D: β-cell destruction. Thus, novel 
techniques are discussed with the potential to gauge degrees of β-cell stress and failure via protein, 
RNA, and DNA analyses.
The discovery and subsequent development of recombinant human insulin, designer insulin 
analogs, sophisticated insulin pumps, and sensors as therapies for type 1 diabetes (T1D) 
represent collectively a remarkable therapeutic achievement. However, insulin is not a cure, 
and T1D remains an irreversible and progressive disease with life-threatening complications. 
In light of this, there remains a tremendous need for continued research into primary and 
secondary prevention strategies as well as improvements in treatment modalities.
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One major hindrance in the design of effective prevention studies is the lack of precise 
biological measures to detect individuals early during their course of β-cell decompensation. 
The latent period in the progression to T1D can be defined as the period during which 
indolent β-cell immune destruction has started, yet adequate residual insulin-secreting β-
cells remain to prevent overt hyperglycemia. This period is clinically silent and 
characterized by β-cell stress, β-cell destruction, insulitis, and autoimmunity.1,2 During the 
preclinical stage of progression to T1D, there is an associated decrease in β-cell function as 
measured by β-cell glucose sensitivity during oral glucose tolerance testing.3 The length of 
this “prediabetic” period is unpredictable, sometimes lasting for just a few months and 
sometimes spanning many years.4
Before the implementation of prevention modalities, especially those that have significant 
risks, biomarkers and diagnostic tests that can indicate accurately the impending 
development and progression of T1D need to be established. These tests may also shed light 
on novel mechanisms leading to the development of T1D. Risk scores have been developed 
to determine which antibody (Ab)-positive relatives of persons with T1D are most likely to 
develop T1D during the subsequent 5 years, yet the positive predictive power of these scores 
before the development of dysglycemia remains insufficient to provide a precise prognosis 
for a given individual.5 Yet, it is during this time that immunomodulatory therapies targeted 
to prevent irreversible loss of β-cells may be most efficacious. Clinical intervention trials 
have been most successful in individuals with greater residual insulin production and those 
with the least time since disease onset.6–8
This systematic review aims to highlight established and emerging biomarkers in the 
detection of incipient T1D. Using a systematic literature review, we identified an array of 
available or emerging biomarkers to detect β-cell autoimmunity or loss of β-cell mass. These 
include genetic markers, autoantibodies, cellular immunity markers, risk score quantification 
techniques, and β-cell stress markers (Fig 1, A).
REVIEW METHODS
We searched Medline, OVID, and EMBASE for English-language articles published 
between January 2003 and March 2013. We used the following phrases: predictive type 1 
diabetes markers, detection of β-cell death, biomarkers in type 1 diabetes, and immune auto-
antibody markers type 1 diabetes. Two reviewers conducted these searches and results were 
combined. Titles and abstracts of articles were screened initially to identify those most 
relevant to the topic area of bio-markers predictive of T1D. Articles were retrieved and then 
screened secondarily based on topic, information relevance, and redundancy of material with 
other identified resources.
This review conforms with relevant ethical guidelines pertaining to the use of humans and 
animals in research.
REVIEW RESULTS
Our initial search yielded 317 citations. Of these, 72 citations were identified that referred to 
markers in T1D. Nineteen articles were identified as relevant for the purposes of this review. 
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Five additional articles were identified for this review using the references of articles found 
in the secondary screen (Fig 1, B). Table I provides a list of the articles covered in this 
review and the category of biomarkers the article covered.
DISCUSSION
Genetic markers in the prediction of T1D
T1D usually arises in individuals who have both a genetic susceptibility and subsequent 
exposure to elusive environmental factors. Although only 10% of individuals with T1D have 
a positive family history, this genetic predisposition puts first-degree relatives at a 20-fold 
increased risk of disease.9–11 Therefore, further refinement of genetic markers that predict 
susceptibility to or protection against disease may assist in identifying those individuals with 
the greatest lifetime risk, and may allow therapies to be targeted to those already in the latent 
period of T1D development.
Human leukocyte antigen (HLA) genes and non-HLA genes play roles in the genesis of 
T1D. HLA corresponds to the major histocompatibility complex genes in humans. HLA 
genes are responsible for cellular immune responses and play a key role in autoimmunity.12 
Certain HLA-DR and HLA-DQ genetic polymorphisms (in particular, HLA-DR3 and DR4 
at the DRB1 locus) are well known to be associated with increased T1D risk.13 Three 
specific HLA polymorphisms confer the greatest risk for developing T1D (Table II14). The 
greatest predisposition occurs with commonly abbreviated short serology notation DR3/
DR4. Children heterozygous for the high-risk DR3/DR4 genotype have a 1 in 20 chance of 
developing T1D by the age of 15 years.14 Conversely, HLA-DR2 is associated with 
protection from T1D development and is linked to the most common DR-DQ haplotype in 
whites.
More than 40 non-HLA genes are also known to contribute to the risk of T1D, although with 
much more modest effects than HLA genes.15 Disease-associated single nucleotide 
polymorphisms (SNPs) have been found in genes including insulin (INS), protein tyrosine 
phosphatase nonreceptor type 22 (PTPN22), interleukin 2 receptor alpha (IL2RA), SH2B 
adaptor protein 3 (SH2B3), protein tyrosine phosphatase nonreceptor type 2 (PTPN2), C-
type lectin domain family 16 member A (CLEC16 A), ubiquitin associated and the SH3 
domain containing A (UBASH3A), and cytotoxic T-lymphocyte-associated protein 4 
(CTLA4).15,16 SNPs in these genes have been used to stratify risk further in persons with 
high-risk HLA genotypes.17 In the Diabetes and Autoimmunity Study in the Young 
population 1743 non-Hispanic white individuals (861 first-degree relatives of T1D and 882 
from the general population) with high-risk HLA genotypes were monitored prospectively 
for the risk of developing islet autoimmunity and T1D.17,18 Multivariate analyses adjusting 
for family history of T1D and HLA high-risk genotype were done to find hazard ratios for 
each of the significant SNPs. Four of 20 examined SNPs had increased hazard ratios for the 
development of islet autoimmunity, T1D, or both: PTPN22 UBASH3A, PTPN2, and INS 
(Table III).
Polymorphisms in the PTPN22 and UBASH3A genes are associated with gain-of-function 
mutations in tyrosine-specific phosphatase signaling, leading to auto-immunity associated 
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with T1D and other autoimmune disorders such as rheumatoid arthritis, systemic lupus 
erythematosus, and Graves’ disease.15,16 PTPN22 and UBASH3A have been associated both 
with the onset of islet autoimmunity and T1D development. PTPN2 is another protein 
tyrosine phosphatase also associated with several autoimmune diseases, including T1D, 
rheumatoid arthritis, Crohn’s disease, and celiac disease. PTPN2 SNP analysis modestly 
predicted the presence of islet autoimmunity. SNPs in INS were also associated with T1D 
development17 (Table III).
Recently, the histone deacetylase SIRT1 gene has been emphasized as a β-cell gene that 
modulates the development of T1D. SIRT1 is involved in nuclear transcription, DNA 
replication, and DNA repair. It is expressed predominantly in β cells, where it appears to 
play key roles in the regulation of insulin secretion, prevention of β-cell apoptosis, and 
cytokine production.19,20 An autosomal dominant mutation in SIRT1 has been reported in a 
family with predisposition to early-onset T1D.21 Interestingly, misexpression of this mutant 
form of SIRT1 in a β-cell line resulted in an increased inflammatory response to cytokine-
mediated signaling. These findings describe a novel monogenic form of T1D and indicate a 
possible role for the modulation of β-cell gene expression in T1D.
With increasing ease of genetic screening, it is likely that a combination of HLA and non-
HLA predictive gene polymorphisms will prove useful in refining risk estimations for 
development of T1D in both relatives of persons with T1D as well as in the general 
population. Yet, genetic predisposition information alone will likely not indicate precisely 
when a given individual will develop T1D, given environmental influences on disease. 
Therefore, there remains a continued need for exploration of nongenetic markers that can 
work coherently with genetic information to elucidate the timing of the onset of T1D.
Autoantibody markers
Islet cell autoantibodies (ICAs) were first reported approximately 40 years ago using 
immunofluorescence assays.22 Autoantibodies have been crucial in establishing T1D as an 
autoimmune disorder. With the reporting of autoantibodies in pancreatic islet cells in 1974 
in a subset of patients with diabetes, evidence to support the hypothesis of insulitis in T1D 
was elucidated. Detection of varying autoantibody titers in patients with diabetes was the 
first indicator of a humoral component to T1D.22
From then to now, new islet cell-associated Ab targets have been established, and 
autoantibody panels are used more frequently to identify individuals at risk for the 
development of T1D and to confirm clinically diagnosed T1D at onset of disease. 
Commercially available T1D-associated autoantibodies include those detecting antibodies to 
insulin (insulin autoantibodies [IAAs]), glutamic acid decarboxylase (GAD), the tyrosine 
phosphataselike insulinoma antigen 2 (IA2) and islet cell antibody 512 (ICA512), the latter 
with autoreactivity to the predominant C-terminal epitope of IA2. Rates of positivity for islet 
antigen-specific autoantibodies at onset of T1D for individuals from the general population 
have been reported23 and are as follows: ICA, 70%–80% of individuals; IAA, 60% of 
children; IA2, 60% of individuals; and GAD, 70%–80% of individuals.23–25 Secondary 
screening for antibodies to cytoplasmic ICA in GAD and IA2 Ab-positive first-degree 
relatives of persons with T1D can detect individuals at greater risk for T1D. Additional 
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positivity for Ab’s to cytoplasmic ICA can further predict a more rapid progression to T1D 
than Ab’s to GAD and IA2 predictions alone.26
Autoantibodies to zinc transporter 8 (ZnT8) documented in 2007, are a relatively new 
addition to this armamentarium.25 ZnT8 is a multispanning trans-membrane cation efflux 
transporter expressed in pancreatic islets.27 ZnT8 autoantibodies can be detected in the 
serum of individuals with prediabetes and persist in individuals with longstanding T1D. 
ZnT8 Ab’s have been reported to be present in 63% of individuals with new-onset T1D. As 
evaluated in 223 individuals with new-onset T1D, the addition of this autoantibody to the 
biochemical panel reduces the number of autoantibody-negative individuals with new-onset 
T1D from 5.8% to 1.8%. A panel of 4 auto-antibodies—IAA, IA2, GAD, and ZnT8—is 
estimated to detect 98% of individuals as autoimmune reactive at the time of onset of 
T1D.25
The true power of ZnT8 autoantibodies stands in their combined use with the established 
biochemical autoantibodies to enhance T1D development predictions significantly.25,28 In 
2256 first- and second-degree biochemical Ab-positive relatives of T1D subjects screened 
through the Type 1 Diabetes TrialNet natural history study, adding ZnT8 in a sequential 
fashion to individuals positive for GAD, IA2, or IAA identified individuals at greater risk of 
T1D. Seventy-five percent of this cohort was positive initially for only 1 biochemical 
autoantibody. When ZnT8 was added, 8% of these individuals were also ZnT8 Ab positive. 
ZnT8 Ab positivity increased the 4-year estimated risk of development of T1D from 7% to 
31%.28 Concentrations and prevalence of ZnT8 Ab increase with age.25 In the European 
Nicotinamide Diabetes Intervention Trial cohort of 526 ICA Ab-positive first-degree 
relatives of individuals with T1D, including ZnT8 Ab in low-genetic risk individuals and 
individuals older than 20 years augmented prediction of T1D.29
The ZnT8 example illustrates how the detection and implementation of additional 
autoantibodies in screening has the potential to hone the prediction of individuals at risk. 
Additional biomarkers such as proinsulin autoantibodies, carbonic anhydrase autoantibodies, 
lactoferrin autoantibodies, GM2-1 islet ganglioside autoantibodies and heat shock protein 
antigens have been identified, but currently these assays need refinement of their sensitivity 
and/or specificity before being able to be implemented in screening.23 Proinsulin 
autoantibodies have been reported in 7.4% of first-degree relatives of persons with T1D vs 
1.9% of the control population.30 Interestingly, in Japan, autoantibodies to the exocrine 
pancreas-associated molecules carbonic anhydrase II and lactoferrin have been reported in 
both autoantibody-positive and -negative subjects with T1D. Both of these autoantibodies 
have also been reported in other autoimmune conditions.31 GM2-1 islet ganglioside 
autoantibody has been reported in individuals with new-onset T1D but not in age-matched 
control subjects. In addition, the presence of this autoantibody at onset correlated 
significantly with the GAD Ab presence in patients.32
Autoantibodies, although reflecting immune activity, may not always mediate tissue 
destruction. However, immunoglobulin (Ig) G antibodies, which predominate in T1D, can 
cause cellular cytotoxicity and are felt to be indicative of greater risk. Some, but not all, 
studies have indicated that changes in response from IgM to IgG1 and IgG3 antibodies may 
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occur before the onset of T1D.33 This indicates that examination of autoantibody isotypes 
may be useful in following and understanding the pathogenesis of T1D.
Beyond the presence or absence of specific autoantibodies, the number of autoantibodies 
and titers of a specific autoantibody are also useful in predicting T1D. This was verified by a 
prospective analysis done on a total of 29,035 relatives of individuals with T1D screened 
and enrolled in the Diabetes Prevention Trial 1 (DPT-1).24 The cohort included a DPT-1 
screened-only group of 28,507 individuals (97.6% ICA-negative individuals) and a DPT-1 
enrolled cohort of 528 individuals (ICA-positive with glucose metabolic impairment). Ab’s 
to ICA, GAD65, and ICA512 were all similarly significant in predicting T1D when 
evaluated as a screened, single positive autoantibody and, when added as a autoantibody 
screened secondarily in persons with 1 prior positive autoantibody, the predictive power for 
T1D increased significantly. As a single autoantibody screen and when added as a second 
autoantibody screen, IAA did not have significant predictive ability in predicting T1D onset.
Most studies to date using autoantibodies to predict T1D have been done in relatives of 
persons with T1D, in whom there is the greatest prior probability of disease (approximately 
5%). It is estimated that 90% of persons with new-onset T1D have no prior family history of 
T1D9; thus, general population screening is needed to identify T1D in persons with no 
known family history of disease. Because both the presence and the number of 
autoantibodies are predictive of T1D, some efforts are focused on developing high-
throughput screening of serum for autoantibody detection. During a 15-year and 27-year 
period, the predictive ability of GAD and IA2 Ab’s were evaluated in 2 study populations: 
first-degree relatives (n = 755 from the Childhood Diabetes in Finland Study)34,35 and the 
general population (n = 3475 from the Study on Cardiovascular Risk Factors in Young 
Finns).35,37,38 Testing positive for a single Ab was associated with a greater cumulative 
disease risk in first-degree relatives than in the general population. However, for those who 
were positive for 2 autoantibodies, the cumulative disease risk was of the same magnitude 
(Table IV). Any individuals with double positive autoantibodies are at an extremely high 
risk of developing T1D. The authors concluded that, in the Finnish population, general 
childhood screening for GAD and IA2 Ab’s would identify ~60% of those individuals who 
would develop T1D during the next 27 years.36 Although this study was conducted on the 
Finnish population, which has a high prevalence of T1D, with the advent of high-throughput 
autoantibody platforms, multiple autoantibody screenings in populations with lower disease 
prevalence is becoming increasingly less costly.
Although the identification of detectable autoantibodies has marked a large step forward in 
predicting T1D, autoantibody assays in differing labs sometimes have widely divergent 
sensitivity and specificity, and differing absolute values for autoantibody titers.37 This has 
led to efforts to standardize and harmonize laboratory assays detecting autoantibodies so that 
results will be consistent and interpretable across sites. This includes the Diabetes Antibody 
Standardization Program workshops, an international initiative aimed to evaluate laboratory 
performance, to improve measurement of autoantibodies associated with T1D, and to 
establish reference ranges for autoantibodies. These workshops have provided evaluation 
data on autoantibodies to insulin, IA-2, GAD, and ZnT8 that have been instrumental in 
progressing the effort toward standardized assays.37–40 These efforts have improved the 
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reliability of certain autoantibody assessments.39 Harmonized autoantibody detection is 
critical before conducting large-scale screening of persons to determine risk of T1D.
The HLA genotype also appears to have an influence on the specific islet autoantibodies 
expressed during the course of T1D development.33 Associations between HLA-DRQ8 and 
IA2-A and IAA, HLA-DR4 with IA2-A and IAA, HLA-DR3 and GAD65, and HLA-DR2 
and GAD65 have all been reported.41–43 However, the presence of a particular HLA 
genotype is neither necessary nor sufficient, even in persons with T1D, to result in a 
particular autoantibody profile.41 The mechanisms of these genetic/humoral interactions still 
need to be elucidated as well.
Although the detection of autoantibodies has been important in identifying individuals at 
risk for T1D, there are still many limitations in their overall usage. An autoantibody panel of 
IAA, IA2, and GAD at the time of onset of T1D will identify approximately 20% of 
individuals with clinical T1D as autoantibody negative, and thus provide false-negative test 
results.27 Autoantibodies also do not provide precise determination of the time frame to 
onset because they can be detected many years before the clinical onset of T1D. In addition, 
the presence of autoantibodies does not mandate the development of T1D, because only 
40% of ICA-positive relatives develop T1D within 10 years.44,45 Furthermore, autoantibody 
titers in those who will develop T1D do not always increase as disease onset nears, but 
rather can wax and wane during the prediabetes period.36 Also, although high-risk genetics 
and the presence of autoantibodies are both related to the diagnosis of T1D, for an individual 
they are not entirely prognostic, particularly in individuals with high-risk HLA and 
autoantibodies selected from the general population. In particular, in a Swedish study, 
adding GAD autoantibody screening to HLA screening in the general population was 
insufficient to improve T1D risk assessment to a clinically significant degree.41
Interesting new data suggest that differences in metabolomic profiles, particularly lower 
methionine concentrations, are found in children who develop autoantibodies.46 Whether 
these profiles persist beyond the development of autoimmunity or are predictive of T1D 
onset remains to be seen.
Risk score quantification
None of the T1D autoantibodies currently have high enough specificity or are available in 
high enough throughput methods to be used for routine population screening. Designing 
“risk scores” based on other clinical criteria brings us 1 step closer to identifying more 
accurately individuals in the prediabetic phase, thereby supplementing autoantibody 
screening. Numerous attempts to quantify risk have been made. All calculations use 
different continuous (eg, age, body mass index [BMI]) or categorical (eg, gender) 
characteristics with a goal of quantifying the likelihood that an individual is in the latent 
phase toward the development of T1D. Data from the DPT-1 have been used to develop a 
DPT-1 risk score (DPTRS) for the prediction of T1D in first- and second-degree ICA-
positive relatives of persons with T1D.5 The score uses age, BMI, fasting C-peptide levels, 
and total glucose, and total C-peptide derived from a 2-hour oral glucose tolerance test. The 
DPTRS can be converted to a 5-year risk estimation for T1D.5 The DPTRS has been 
validated in the TrialNet population of relatives of individuals with T1D with at least 1 
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detectable autoantibody.47 This score can also be used to monitor the progression to disease 
and to target the greatest risk individuals for intervention studies. However, work has not 
been conducted to demonstrate the predictive ability in the general population.
Receiver-operating characteristic curves have been used to combine immunologic and 
metabolic parameters in predicting T1D in DPT-1 study population members with 
diminished first-phase insulin response and/or abnormal glucose tolerance.48 After testing a 
variety of variables, including Ab titers for ICA, IAA, ICA512, GAD65, fasting insulin 
concentrations, fasting glucose levels from oral glucose tolerance tests and IVGTT, first 
phase insulin response, and peak C-peptide, adding a combination of 2-hour glucose, peak 
C-peptide, and area-under-the-curve C-peptide improved significantly the prognostic 
accuracy compared with any single variable. Adding age, sex, and BMI to the model did not 
improve the prediction accuracy. Interestingly, like the DPTRS model, this model does not 
incorporate any autoantibody measures (such as number of autoantibodies or Ab titers) 
except that all individuals were ICA positive. It is possible that autoimmune reactivity may 
not affect risk greatly after metabolic function has declined significantly.48
Mrena et al49 present a strategy for the identification of siblings of children with new-onset 
T1D who will possibly progress to T1D. Using Cox regression analysis they identified the 
following factors as useful in predicting those who will progress to T1D: age, HLA-DR 
conferred susceptibility, increased number of autoantibodies, decreased first-phase insulin 
response, and reduced insulin sensitivity relative to insulin secretion. Uniquely, this group 
went further to develop models to predict age at T1D diagnosis based on subject age, age of 
sibling T1D diagnosis, IA2 Ab levels, the number of autoantibodies present, HLA-DR 
conferred susceptibility, and initial first-phase insulin response level. The model predicting 
age at diagnosis worked well for individuals in the cohort who were true progressors to 
T1D, but was not adequate in predicting age of onset of T1D for those who did not progress 
to a diagnosis of T1D during the study period. In the models used, all nonprogressors were 
falsely predicted as progressors to T1D within the study observation period.
Although diabetes risk scores establish a probability of the eventual clinical onset of T1D, 
this method of prediction does not assess the degree of ongoing autoimmune disease or β-
cell failure. There are proposed biologic markers that can measure directly the level of 
immune activation. These markers can, potentially, be incorporated into screening Ab’s and 
risk scores. Combining these predictive indicators has the potential not only to identify 
prediabetic status, but also to suggest a physiological marker of the level of immune 
activation.
Cellular immune reaction markers
T1D has a large humoral and cellular inflammatory component. Yet, humoral activation in 
T1D as evidenced by the magnitude of autoantibody titers does not always correlate with 
cellular immune system activation.50 Furthermore, Ab titers do not correlate with the overall 
severity of the autoimmune disease or provide clues about the time to clinical disease onset. 
Even with the accepted autoimmune nature of T1D, a case of development of T1D in a 
patient with X-linked gammaglobulinemia who was B-cell deficient with normal T-cell 
function highlights a role of the cellular immune system in the development and progression 
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of T1D.51 There are currently no available clinical measurements of the degree of cellular 
immune system reactivity specific to the T1D immune activated state. Yet, there is the 
potential for exploring cellular immune system activation in T1D as a biomarker.
Mechanistic T-cell activation markers
T1D is mediated by T-cell activation leading to β-cell destruction. In the past, efforts to 
develop T-cell reactivity assays focused on quantitating CD4+ T-cell subsets in T1D. 
However, CD8+ T cells are now proposed to be an important mediator in the pathway to 
T1D development, because insulitis has been shown to be driven by CD8+ T cells in 
nonobese diabetic (NOD) mice.52,53 CD8+ T-cell populations have been studied using 
immunoblots, enzyme-linked immunospots (elispots), and tetramers as a means of 
differentiating between individuals with new-onset T1D and healthy subjects.54 Islet-
specific interferon-gamma CD8+ T-cell responses, ISL8Spot, have the potential to serve as a 
new immune marker of T1D.54 An assay using a panel of HLA-A2-restricted β-cell epitopes 
derived from 15 epitopes including preproinsulin, GAD, and islet glucose-6-phosphatase 
catalytic subunit-related protein run on unfractionated peripheral blood mononuclear cells 
without preliminary expansion differentiated patients with new-onset T1D effectively from 
healthy control subjects (sensitivity, 86%; specificity, 91%). Interestingly, in the healthy 
cohort the T-cell reactivity assay identified positively an individual who was clinically 
healthy but contained the T1D predisposing HLA-DR3 genotype and positive titers for IAA.
When combined with autoantibody assays, T-cell responses using immunoblot and T-cell 
proliferation assays in 1 study showed 75% sensitivity and 100% specificity in 
differentiating persons with T1D from control subjects.55 This highlights the potential for 
these sorts of T-cell assays also to differentiate individuals in the prediabetic stage of T1D; 
however, further validation of these assays is needed.
Serum cytokine assays
Cytokines have also been explored as a marker of T1D in persons 1–40 years after 
diagnosis.56 One example is chemokine ligand 1 (CXCL1) measured in sera using solid-
phase enzyme-linked immunosorbent assays. CXCL1 is released by monocytes, dendritic 
cells, and pancreatic β cells and induces T-cell chemotaxis. In persons with T1D, CXCL1 
concentrations are increased relative to individuals with type 2 diabetes (T2D). Elevations of 
CXCL1 have also been reported in other autoimmune conditions. CXCL1 has potential as a 
marker of incipient T1D, but first needs to be validated in healthy control subjects and 
populations with prediabetes.
β-cell function markers
Ultimately, T1D is characterized by β-cell stress and eventual apoptosis.57 At the time of 
clinical onset of T1D, approximately less than 20%–30% of functional β-cell mass remains. 
Even with genetic screening, autoantibodies, cellular immune system activation 
assessments, and risk score quantification, the crucial problem of irreversible β-cell death 
has only recently been considered as a potential biomarker. In light of the current inability to 
detect insidious β-cell death before the onset of overt hyperglycemia, markers of β-cell stress 
and destruction may be useful in identifying individuals with prediabetes. Ideally, these 
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markers could be among the earliest indicators to predict onset and the degree or severity of 
β-cell loss of homeostasis in the progression to the development of T1D. There are several 
assays with the potential for detecting β-cell destruction at the levels of DNA, RNA, and 
protein.
β-cell specific DNA
Quantitative polymerase chain reaction techniques can be used for systemic detection of 
demethylated insulin DNA as a marker of β-cell death. Increased β-cell-derived DNA has 
been observed in streptozotocin β-cell toxin-induced diabetic and NOD mice before 
hyperglycemia. In patients with new-onset T1D, increases in demethylated insulin DNA 
have been observed compared with age-matched control subjects.58,59 This technique was 
implemented recently to quantitate β-cell death using serum samples obtained during an 
intervention trial with teplizumab. Improvements in C-peptide responses with immune drug 
intervention were associated with decreased demethylated insulin DNA.59 Further 
development of this methodology is still needed, because it has not yet been evaluated in 
individuals who are in the latent/prediabetic phase of disease as a predictive marker.
β-cell specific RNA
In T1D, the activation of specific β-cell health maintenance pathways such as oxidative 
stress or endoplasmic reticulum (ER) stress during the course of T1D can lead to increased 
expression of specific microRNAs (miRNAs). miRNAs are known to play a central role in 
posttranscriptional gene regulation, cellular differentiation, proliferation, and apoptosis. 
However, the mechanism of their upregulation is not fully known.60 Specific miRNA 
expression has been explored as a marker for T1D glycemic control and residual β-cell 
function in the T1D population.61 In individuals with new-onset T1D 1 month after 
diagnosis relative to age-matched healthy control subjects, 12 miRNAs were upregulated, 
several of which were linked to apoptosis and β-cell gene regulatory networks.62,63 Of 
significance, miR25 levels present soon after diagnosis were associated with β-cell function 
as measured by improvements in stimulated C-peptide and with hemoglobin A1C levels 3 
months after diagnosis.
The possibility that miR-375, an islet-cell-specific miRNA,64 might be used to detect 
prediabetes has been explored.65 Similar to demethylated DNA, it is proposed miR-375 is 
released from β cells during apoptosis. Studies using streptozotocin-treated and NOD mice 
have shown increased levels of miR-375 before hyperglycemia. These studies must be 
verified in human subjects. However, these studies indicate a specific miRNA may have 
potential as a biomarker of β-cell function before the onset of T1D and in very early T1D to 
identify individuals for β-cell sparing or regenerative therapies.
These studies allude to the biomarker potential of miRNAs in T1D as a means to quantify β-
cell function. As biomarkers, miRNAs show great potential. They are stable under harsh 
conditions and can be detected easily in bodily fluids such as plasma and serum. In addition, 
quantification of miRNAs using quantitative real-time polymerase chain reaction techniques 
may offer sensitive and specific assays.60 One potential limitation to the usage of miRNA as 
a biomarker is the uncertainty of the source of detected miRNA, because it is difficult to 
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show isolated release from islet β cells. There is still a significant amount research needed 
before miRNA can be used as a clinical marker of T1D onset and progression, but it holds 
tremendous potential.
β-cell-specific proteins
β-cell stress was thought originally to be a phenomenon primarily of persons with T2D, but 
has since been investigated in T1D.66,67 Proinflammatory cytokines are proposed to be 
responsible for ER stress observed in T1D whereas glucolipotoxicity is proposed as a 
causative factor in T2D ER stress. In human pancreatic islet autopsy specimens, the ER 
stress markers C/EBP homologous protein and immunoglobulin heavy chain have been 
detected in insulitis-positive islets. There is potential for using ER stress markers as a 
detection tool or marker of the level of intrinsic β-cell function in persons with T1D. 
Secreted molecules from ER-stressed β cells may be used as early markers of preclinical 
T1D.67,68
Tersey et al67 validated the theory that β-cell ER stress precedes the onset of hyperglycemia 
in the NOD mouse model, with both morphologic changes and secretory functional changes 
in the ER. In NOD mice during the prediabetic phase, there is ER loss of homeostatic 
function accompanied by increases in serum proinsulin and decreases in insulin production. 
Increased serum levels of proinsulin compared with serum levels of the fully processed 
insulin molecule (assessed by measuring C-peptide), the proinsulin-to-C-peptide (PI:C) ratio 
has potential as a diagnostic marker of individuals during the latent period of β-cell failure 
with escalating amounts of ER stress. As a biomarker, this will be able uniquely to measure 
directly the functional ability of the pancreatic β cells, and there is potential to quantify the 
severity of β-cell dysfunction during the preclinical stages of T1D development.
An increased ratio in the random serum PI:C ratio has been shown to precede the onset of 
T1D.69 Truyen et al70 reported that random PI:C measurements complement autoantibody 
status in first-degree relatives of individuals with T1D in assessing the risk of T1D 
development. The predictive power of PI:C to assess β-cell function is evident in findings of 
similar glycemic control between the autoantibody-positive relatives cohort and the 
autoantibody-negative relatives cohort; but, significant elevation of PI:C was detected in the 
autoantibody-positive cohort. The PI:C levels in the autoantibody-negative cohort were not 
distinguishable from the general population cohort. Of note, the elevation of PI:C correlated 
significantly with the number of autoantibodies present and was also elevated more 
strikingly in individuals with prediabetes who were sampled within 40 months of diagnosis.
CONCLUSION
This review has explored a variety of biomarkers in the field of T1D. We discussed genetic 
markers, autoantibody markers, risk score quantification, cellular immune system markers, 
and indicators of β-cell stress/death. The number of potential biomarkers discussed here and 
the varying pathophysiological basis of their use in the analysis of T1D pathogenesis and 
progression highlight recent progress in the field of T1D research. However, at the level of 
the individual subject, where prognostication may matter most, the predictive value of any 
individual biomarker “signal” is generally limited. Currently, there remains no single major 
WATKINS et al. Page 11
Transl Res. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
test or combination of tests that can detect individuals definitively during the latent phase as 
they progress toward the development of T1D, and it is evident that continued research is 
still warranted.
Although these numerous techniques may, individually, hold great potential in diagnosing 
T1D before the clinical onset of disease, one must pause to consider the obstacles or 
hindrances that broadly limit these methods of testing. Perhaps, instead of looking to 
develop a single marker to detect preclinical T1D accurately and universally, efforts should 
be focused on the combined usage of multiple biomarkers in validated risk algorithms. Also, 
longitudinal data will be necessary to assess how panels of biomarkers change over time 
throughout the progression of T1D.
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Fig 1. 
(A) Depiction of predictive markers in the type 1 diabetes (T1D) field. (B) Flowchart 
presentation of the selection method used for identifying articles in the systematic review. 
HLA, human leukocyte antigen; miRNA, microRNA.
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Table II
Odds ratio of developing T1D based on the HLA genotypes with greatest susceptibility and the most common 
genotype with protective association
Genotype Full name Odds ratio (95% CI)
DR3/dr4 T1D DRB1*03:01-DQA1*05:01-DQB1*02:01 and DRB1*04:01/02/04/05/08DQA1*03:01-
DQB1*03:02/04 (or DQB1*02)
16.59 (13.70–20.10)
DR3/DR3 DRB1*03:01-DQA1*05:01-DQB1*02:01 6.32 (5.12–7.80)
DR4/DR4 DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*03:02/04 5.68 (3.91–8.23)
DR2/DR2 DRB1*15:01-DQA1*01:02-DQB1*06:02 0.03 (0.01–0.07)
Abbreviations: CI, confidence interval; HLA, human leukocyte antigen; T1D, type 1 diabetes.
Adapted from Noble et al14
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Table IV
Cumulative disease risk in the general population representation group and in first-degree relatives of 
individuals with T1D monitored for a 15-year period35
Antibody Cumulative disease risk, % (95% CI)
GAD Ab IA2 Ab General population group First-degree T1D relative group
+ − 24 (9–38) 61 (48–74)
− + 32 (12–51) 74 (61–88)
+ + 86 (60–100) 83 (69–97)
Abbreviations: Ab, antibody; CI, confidence interval; GAD, glutamic acid decarboxylase; IA, insulinoma antigen 2; T1D, type 1 diabetes.
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